32 research outputs found
Flow Cytometry in Pediatric Malignancies
No full textAbstract
The utility of flow cytometry as a useful diagnostic modality for the assessment of hematopoietic neoplasms has been established beyond doubt. In fact, it is now an integral part of the diagnosis and classification of various diseases like leukemias and lymphomas along with molecular studies and cytogenetics. Prognostication and disease monitoring by flow cytometry is also being recognized increasingly as one of the important fortes. This is evident by the number of articles in the published in literature on the minimal residual disease detection by flow cytometry especially in the last decade or so. To add to this, ever growing list of utilities in hematopoietic malignancies, many nonhematopoietic neoplasms can also be analyzed by flow cytometry. The examples include fluid specimens from serous cavity effusions and samples from solid tissues like lymph nodes, reticulo-endothelial tissue, central nervous system tissue, etc. Flow cytometry technique provides a unique blend of rapidity, high sensitivity and specificity compared to cyto-morphology and conventional immunohistochemical staining. It is also remarkable for simultaneous analysis of more than one marker on the cells. Evaluation of limited samples such as cerebrospinal fluid or fine needle aspiration samples makes Flow cytometry a valuable tool. DNA ploidy analysis and assessment of pediatric non-hematopoietic neoplasms by Flow cytometry has envisaged the utility vista of this technique. This review is aimed at providing an insight into the applications of flow cytometry in pediatric malignancies.</jats:p
Are we missing out something in donor notification?
No full textBackground: Donor notification is an integral part of any blood collection facility. But regarding DAT positive donors there are no standard guidelines to notify them or to refer them to any clinician. Aim of this study was to suggest possible ways to manage DAT positive donors. Material and Methods: This was a retrospective study extended over past 5 years from 2013-2017 in a tertiary care health center. All whole blood donations were tested for ABO Rh, irregular antibody, HIV, HBV, HCV, SYPHILIS, and Malaria parasite. At the time of blood request if crossmatch came incomnpatible and antibody screen was negative we do DAT of the unit and if it comes positive then DAT work up was done. Result: Of total 55,310 donations, Twenty-two (0.04%) donors were DAT positive. From DAT positive donors, in 72% of cases IgG alone was responsible for DAT positivity of the unit, and in 18% of cases, involved IgG was subtyped as I gG1/IgG3. Conclusion: With the evidence of a significantly increased risk of cancer, especially hematologic malignancies, among blood donors with a positive DAT, donor notification is suggested. There should be a standardized protocol across the country about donor notification to avoid confusion and variations seen in different blood collection facilities
Biphenotypic extramedullary blast crisis with MLL gene rearrangement in a case of chronic myeloid leukemia following Dasatinib therapy: An unusual case
No full text
Fatty but starving marrow! Gelatinous transformation of bone marrow secondary to plasma cell disorder and all-trans-retinoic acid therapy: A report of two cases
No full text
Donor registration management using blood bank information system: Added layer to safe blood in developing country
No full textMaking type and screen policy an essential component of pretransfusion testing: Need of the hour in India
No full textIntroduction: “Type and screen” policy involves the prior determination of patient blood group and antibody screening at the time of admission irrespective of the need of the blood transfusion to the patient. Materials and Methods: As a part of our retrospective analysis, we have evaluated our data from January 2014 to June 2016. Blood grouping was done by column agglutination technology (CAT) using DiaClon ABO/D+ Reverse Grouping cards (BIO-RAD, Switzerland). Antibody screening and identification were done using three cell panels (ID-DiaCell I-II-III Asia panel by BIO-RAD, Switzerland) and 11 cell panels (ID-DiaPanel-P by BIO-RAD, Switzerland) on CAT with LISS/Coombs cards. Results: A total of 17,896 patients requests for “type and screen” were received by the department during the study. Out of which 201 (1.12%; 1 in 89 patients) patients were found to have positive antibody screen. Out of 201 patients (132 females; 69 males); mean age group of 45.6 years (range: 1 day–85 years). Out of 201, 145 patients developed single antibody, 15 patients had double antibody, and in 41 positive antibody screens the specificity of alloantibodies were not identified either due to an interfering autoantibody (n = 10) or the specificity was not resolved on extended panels (n = 31) even with enzymes. Conclusion: “Type and screen” policy helps in timely blood group typing of the patients and providing enough time for the blood bank to arrange for blood. Our analysis shows the presence of an alloantibody in every 89 requests received for “type and screen.
Fatty but starving marrow! Gelatinous transformation of bone marrow secondary to plasma cell disorder and all-trans-retinoic acid therapy: A report of two cases
No full text
